Biotech entity
Of the tracked stories, 4 of 4 also mention Weiss Ratings, the most common co-covered peer. That works out to roughly 4 stories per week across a 7-day span. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 4, with the remainder spread across 2 other categories.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 4 also mention Weiss Ratings, the most common co-covered peer. That works out to roughly 4 stories per week across a 7-day span. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 4, with the remainder spread across 2 other categories. At 5, the average consequence score sits below the same-window beat average of 5.8. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window. We currently track 4 Biotech stories that mention FiscalAI, published between August 16, 2026 and August 22, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 28 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FiscalAI. Shared-story counts are live from our verified record — not editorial picks.
Silexion reports quarterly results
Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Maxim Group downgrades to Hold
Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
Weiss Ratings reiterates Sell (E+)
Weiss Ratings reiterated a Sell (E+) rating on Silexion Therapeutics shares.
Wall Street Zen rating action
Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).
Wall Street Zen downgrades MBRX
Cut its rating from 'sell' to 'strong sell' in a research note
Jane Street Group discloses new MBRX position
Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company
I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Source: Bbns · Ticker Report
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Source: tickerreport.com · dailypolitical.com
FiscalAI is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
